TM4SF5 and hepatocellular carcinoma: These results from in vitro cells, in vivo mice, and clinical patient datasets suggest that hepatocyte TM4SF5 promotes HCC development by downregulating SLAMF7, leading to NK cell inactivation, which can be blocked by anti-TM4SF5 isoxazoles.